Kornimate/medical-research-clean huggingface dataset:
the safety and efficacy of sunitinib in chinese patients with progressive advanced or metastatic well-differentiated unresectable pancreatic neuroendocrine tumors

Conditions: Pancreatic Neuroendocrine Tumors

Summary: this study is a multi-center, prospective, non-interventional (ni) study evaluating the safety and efficacy of sunitinib in chinese patients with progressive, unresectable, advanced or metastatic well-differentiated, pancreatic neuroendocrine tumors(pnet). 100 adults with progressive advanced or metastatic well-differentiated unresectable pnet will be recruited in china hospitals. each subject will be followed up overall survival (os) time or the date of withdrawal and subjects who remain alive after study completion will have their os time censored on the last date known to be alive. eligible subjects will be enrolled to receive at least one dose of sunitinib orally at 37.5 mg once a day on a continuous daily dosing regimen (cdd) or dosage modification is based on daily clinic practice. subjects will be treated until disease progress, unacceptable toxicity, withdrawal from the study at their own request, or until the final analysis for the study is performed. the ni study will capture observations that will be used for evaluating the safety profile of sunitinib, including: subject demographics, medical history and medications. safety assessments, treatment data and any other laboratory examination results, which were done according to routine clinical practice, will be collected at all visits.

the sunitinib non-interventional (ni) study is a real world observational study which represents the usual and customary treatment of patients and being proposed to collect data systematically and to assess the safety and efficacy in chinese patients with progressive, unresectable, advanced or metastatic well-differentiated, pancreatic neuroendocrine tumors.it is designed and conducted to meet cfda post-marketing commitments. non-probability sample

Eligibility criteria:
inclusion criteria: * evidence of a personally signed and dated informed consent document indicating that the subject (or a legally acceptable representative) has been informed of all pertinent aspects of the study. * subjects who are willing to follow up visits within current clinical practice. * histologically or cytologically proven diagnosis of well-differentiated pancreatic neuroendocrine tumors (according to who 2000 classification) * unresectable (as assessed by the investigator) or metastatic disease documented on a scan * a minimum age of 18 years exclusion criteria: * patients with poorly-differentiated pancreatic neuroendocrine tumors (according to who 2000 classification) * patients who have received at least one dosage of sunitinib treatment prior to signing informed consent form will be excluded from participating in this study.
wells and enteric disease transmission trial (wet - trial)

Conditions: Gastrointestinal Infection; Respiratory Viral Infection

Summary: approximately 40 million people in the us are served by private wells, many of which are untreated. the investigators estimate that 1.29 million cases of gastrointestinal illness (gi) per year are attributed to consuming water from untreated private wells in the us. these cases of gi can cause a significant burden in terms of health care costs and lost work/school days, as well as increased risk to developing longer term health complications. this impact is magnified when accounting for vulnerable populations such as children under the age of 5, the elderly and the immunocompromised. the investigators are preparing to conduct the first household randomized controlled trial (rct) to investigate whether consuming well water treated by ultraviolet light (uv) compared to consuming untreated private well water decreases the incidence of self-reported gastrointestinal illness and respiratory infections in children under 5. the investigators will collect illness symptom data using a combination of weekly text messages and online illness questionnaires.


Eligibility criteria:
inclusion criteria: * child resides in berks, bucks, chester, lancaster, lehigh, or montgomery county in pennsylvania * household is served by a private well * participant child is under the age of 5 (under 4 at time of enrollment), who is a full-time resident of the home and drinks untreated well water (75% or more of water consumption must be from untreated well water) * parent/guardian has access to a phone with texting capabilities exclusion criteria: * child participant is immunocompromised * child participant has a chronic gastrointestinal condition * child takes daily oral steroids * household treats water before consumption (with the exception of water softeners)

Keywords: groundwater private wells acute gastrointestinal illness respiratory infection
irritable bowel syndrome and lactibiane tolerance

Conditions: Irritable Bowel Syndrome

Summary: the purpose of this study is to evaluate the effects of a probiotic combination (lactibiane tolerance) on the severity of symptoms in patients with irritable bowel syndrome (ibs).

the primary purpose of this study is to evaluate the effects of a probiotic combination (lactibiane tolerance) on the severity of symptoms in patients with irritable bowel syndrome (ibs). the secondary purposes are to evaluate the effects of the intervention on: * quality of life * severity of fatigue, anxiety and depression * levels of inflammatory markers in blood and tools

Eligibility criteria:
inclusion criteria: * irritable bowel syndrome according to the rome ii criteria * 150\< francis score \< 300 * had score inferior or egal to 25 exclusion criteria: * history of hypersensitivity to one of the composant of the product * use of probiotics or antibiotics last four weeks * use of prohibited drugs * bowel preparation for morphological examination last month * pregnancy or lactation * immundepressed or co-existing other serious illness or evolutive

Keywords: irritable bowel syndrome probiotics
a pilot study of the treatment of facial nodular and nodulocystic basal cell carcinoma with double curettage and cautery followed by application of imiquimod to the base

Conditions: Basal Cell Carcinoma

Summary: the purpose of this study is to determine recurrence rates of nodular basal cell carcinomas on the face removed with curettage and electrodessication (cautery) followed by application of imiquimod cream to the base and further to achieve lower recurrence rates than after treatment with curettage and electrodessication alone.

basal cell carcinomas (bcc) are the commonest form of skin cancer in the white population. the face is where they most frequently occur and the nodular bccs are the commonest type. curettage and cautery/electrodessication (c\&c) has been an established way of management of nodular bccs for years, being a simple surgical procedure readily performed in outpatient clinics with good aesthetic results and high cure rates. the purpose of this study is to determine recurrence rates of nodular bccs on the face removed with c\&c followed by application of imiquimod cream to the base and further to achieve lower recurrence rates than after treatment with c\&c alone. imiquimod is an immune response modifier with anti-tumour effects already licensed for the treatment of superficial bccs in the uk.

Eligibility criteria:
inclusion criteria: * well-defined primary, not previously treated nodulo-cystic bcc * size of the lesions: ≤ 1cm diameter * facial lesions * patient compliance competent * patient physically able to apply the treatment (cream) exclusion criteria: * recurrent lesions * superficial, morphoeic or pigmented bcc * lesions close to vital structures; i.e. where c\&c is not considered a standard treatment (eyelids, inner canthus, free borders) * lesions within 1 cm of the eyelids, nose, lips and hairline * immunosuppressed patients * women in childbearing age, pregnancy and breast-feeding * ages \ 90 * patients compliance incompetent * patients physically incapable to apply the treatment (cream) * patients with gorlin syndrome (nevoid basal cell carcinoma syndrome)

Keywords: basal cell carcinoma curettage imiquimod treatment
statistical basis for hemochromatosis screening

Conditions: Blood Disease; Hemochromatosis

Summary: to determine optimal values for transferrin saturation for use in population screening for hereditary hemochromatosis.

background: once considered to be a rare disorder, hemochromatosis is now recognized to be one of the most common autosomal recessive disorders in white populations. substantial morbidity and mortality may result from untreated hemochromatosis; thus, early detection and treatment are essential. the centers for disease control and prevention and the college of american pathologists now recommend regular screening for hereditary hemochromatosis. transferrin saturation is regarded as the best single screening test for the detection of individuals at risk for the disorder. design narrative: statistical mixture modeling was used to develop guidelines for hemochromatosis screening regimes and to determine the frequency of the gene for hemochromatosis. the research was designed to provide a statistical foundation for the analysis of population transferrin saturations to assist in development of optimal screening regimens for hemochromatosis. to determine potential screening thresholds, probability methods were applied to data from the third national health and nutrition examination survey (nhanes iii), a cross-sectional probability sample weighted to represent the u.s. population. statistical mixture modeling was used to determine potential transferrin saturation screening thresholds to identify individuals for repeat testing and possible further evaluation. the actual sensitivity and specificity of these screening thresholds was then assessed using data from a separate demonstration project, "cost effective hemochromatosis survey in primary care", designed to identify individuals with hemochromatosis. in addition, the gene frequency for hemochromatosis for whites and ethnic subgroups was also determined by analysis of transferrin saturation data from nhanes iii. the study has two specific aims, as follow: (1) to develop guidelines for the use of transferrin saturation and related tests in detection of individuals at risk for hemochromatosis, and (2) to determine the frequency of the gene for hemochromatosis in the united states by statistical mixture modeling of population transferrin saturation data from nhanes iii. providing the statistical foundation for the analysis of transferrin saturations should facilitate development of optimal, cost-effective screening regimens for identification of individuals requiring further evaluation for hemochromatosis. the study completion date listed in this record was obtained from the "end date" entered in the protocol registration and results system (prs) record.

Eligibility criteria:
no eligibility criteria
study of cases of cutaneous leishmaniasis treated with miltefosine in french guiana, retrospective study

Conditions: Cutaneous Leishmaniases; Treatment Adherence; Primary Health Care; Drug Evaluation

Summary: miltefosine is the only oral treatment currently available for cutaneous leishmaniasis. despite several reports of good efficiency in other countries of south america, miltefosine remains limited to a compassionate use in france. the objective of this study is to collect data regarding the efficacy, safety and acceptability of miltefosine in patients treated in french guiana since 2017.

in french guiana, cutaneous leishmaniasis is mostly caused by leishmania guyanensis (80% of cases), followed by l. braziliensis (10%) and rarer species. l. guyanensis is usually treated with a single injection of pentamidine. however, pentamidine-resistant infections (10%) and all l. braziliensis are treated with either amphotericine b or meglumine antimoniate. these treatments can only be used during an hospitalization, which is the source of important indirect costs and discomforts for patients from the remote areas of french guiana. miltefosine is the only oral treatment available for cutaneous leishmaniasis. while it is widely used in south america (with good reported efficacy), the data available in france are scarce. this treatment, if available on a larger scale in france, would allow a treatment without hospitalization, which would be very suitable for french guianese patients. our objective is to collect data on patients already treated with miltefosine in french guiana (current indications being failure, side effect or impossible delivery of amphotericine b and meglumine antimoniate) in order to assess its efficacy, safety and acceptability. patients treated with miltefosine at the cayenne hospital center between 2017 and 2022 will be contacted by phone so as to answer questions regarding their quality of life during the infection and their satisfaction concerning miltefosine as a treatment. data on their symptoms and general informations will be extracted from the medical files. primary objective: to assess the efficacy, tolerance and acceptability of miltefosine among patients already treated with this drug as part of its aac in french guiana. observational, retrospective and prospective, monocentric study research involving human person category 3 (riph3) - non-interventional (rni) - questionnaire (jardé law)

Eligibility criteria:
inclusion criteria: * mucocutaneous leishmaniasis proven by culture and/or polymerase chain reaction (pcr) * seen in french guiana between 01/01/2017 and 01/04/2022, in dispensaries (cdps) or in the dermatology department of the chc * having received treatment with miltefosine * patient who consented to participate in the study * age equal or superior to 18 years exclusion criteria: * clinically suspected but not parasitologically proven leishmaniasis * refusal to participate * age \< 18 * patient under legal guardianship

Keywords: pentamidine amphotericin b meglumine antimoniate oral administration intraveinous administration intramuscular administration french guiana
outpatient treatment of constipation in children

Conditions: Constipation

Summary: constipation is a condition often seen in children. constipation is often associated with impaired quality of life of the child and of great concern among parents. despite the fact that both diagnosis and treatment is a simple task, it is often seen that the treatment fails, and many children are referred to a pediatric ward for specialized treatment. there is currently little research on the subject and treatment is therefore based on expert knowledge rather than scientific research. the study objective is to identify the most effective and least stressful treatment of children with constipation for both families and the health care system. the following will be tested: does treatment of constipation in children require specialized knowledge and extensive resources or can the treatment be simplified? the results from this study are expected to form the basis for a evidence based treatment of children with constipation.


Eligibility criteria:
inclusion criteria: * children between 2 and 16 years and referral to our out patient clinic with either constipation or fecal incontinence. * patients must fulfill the rome iii criteria of constipation, which mean they must have at least 2 of the following characteristics: fewer than 3 bowel movements weekly, more than 1 episode of fecal incontinence weekly, large stools in the rectum by digital rectal examination or palpable on abdominal examination, occasional passing of large stools, display of retentive posturing and withholding behavior, and painful defecation. exclusion criteria: * children with known organic causes of constipation, including hirschsprungs disease, spinal and anal congenital abnormalities, previous surgery on the colon, inflammatory bowel disease, allergy and metabolic or endocrine diseases. * children receiving drugs known to affect bowel function during a 2 month period before initiation.

Keywords: constipation children outpatient
improvement of functional dyspepsia after drinking alkaline ionized water from alkaline ionizer

Conditions: Functional Dyspepsia

Summary: the goal of this clinical trial is to evaluate the effect of drinking electrolyzed alkaline reduced water (earw) compared to drinking purified water (pw) on functional dyspepsia (fd) patients. the main question\[s\] it aims to answer are: * drinking earw (earw group) will alleviate gastrointestinal (gi) symptoms and fd symptoms compared to drinking pw (pw group). * drinking earw will make higher the fd-related quality of life (fd-qol) compared to drinking pw. patients will drink earw 10ml/kg/day body weight for 6 weeks according to the instruction of researcher using the experimental device installed at each patient's house. after 6 week, earw and pw groups will be compared to evaluate effect of gi symptom and fd-related qol.

this study was designed as a randomized, parallel, double-blind controlled clinical trial. enrolled patients with fd will be allocated randomly into two groups: earw group and pw group. for 6 weeks, the patients will drink earw and pw (10ml/kg/day body weight) in empty stomach condition. for the primary outcome measure, the gastrointestinal symptom rating scale (gsrs) will be used, and for the secondary outcome measure functional dyspepsia-related quality of life (fd-qol), and korean version of the nepean dyspepsia index (ndi-k) will be used at baseline and at 6 weeks.

Eligibility criteria:
inclusion criteria: * symptoms onset should start at least 6 months before diagnosis based on one or more of the following symptoms rome iv criteria (unpleasant postprandial fullness, early satiety, epigastric pain, epigastric burning sensation) * no evidence of structural disease in gastroscopy within the last 3 months * aged 19-70 years * who meets rome iv criteria for functional dyspepsia * who have 4 or more symptoms based on the gastrointestinal symptom rating scale * patients who voluntarily agree to participate in this study and sign a written consent exclusion criteria: * subjects who have a history of serious malignancy including gastrointestinal malignancy, cerebrovascular disease, and heart disease within the past 6 months were excluded * subjects who have uncontrolled diabetes and hypertension despite appropriate management * subjects who have a history of peptic ulcer or reflux esophagitis within the past 6 months were excluded * subject who have history of gastrointestinal surgery were excluded * women who are pregnant or breastfeeding * subjects who are taking drugs that may affect the gastrointestinal tract (minimum of 2 weeks washout period is necessary before participating in the trial (medications include h2 receptor blockers, anticholinergics, prostaglandins, proton pump inhibitors, gastromucosal protection agents, corticosteroids, non-steroidal anti-inflammatory drugs, aspirin, mucosal protective agents, etc.) * subjects who are under drugs for therapeutic purposes such as functional food that promotes gastric health * subjects who consumed more than 14 times alcohol per week in case of man and 7 times per week in case of female in the past 1 month
effect of kinesiotape technique on wrist among chronic stroke patients

Conditions: Chronic Stroke

Summary: the aim of this randomized controlled is to assess the effect of kinesiotape technique upon wrist joint among the patients with chronic stroke. patients are devided into groups, in group a kinesiotaping facilitation technique is applied on wrist extensor muscles while inhibition technique is applied on wrist flexor muscles and the result is the compared between the groups and within the group.

stroke is a very common disease worldwide causing severe musculoskeletal disability due to which quality of life of patient compromises, patient becomes dependent of assistance in daily living activities and few becomes bed ridden. stroke also causes death of the patient. apart from musculoskeletal issues patient's cognitive abilities are also effected. it is tough to manage these patients as stroke varies in types and symptoms. symptoms and severity depend upon type of stroke and factors like lifestyle, age and health issues. according to the symptoms different physiotherapy techniques and rehabilitation is used along with medical treatment and counseling of the patient. kinesiotape also has the advantage that it can be worn 3-5 days due to which it's effects remains for long time as compare to other treatments which are given and has effect for a specific time for example a session of physical therapy including exercises is for an hour but this tape can be worn for days once applied. randomized controlled trial was done, 24 patients were recruited according to inclusion exclusion criteria. patients were further divided into two groups; group 1 was given muscular facilitation treatment for wrist extensors and group 2 was given sessions for muscle inhibition treatment for wrist flexors. 6 sessions were given, 1 session per week over the period of 6 weeks to each patient. wrist range of motion for extension, flexion, ulnar and medial deviation was measured using goniometer before and after the 6 weeks. manual muscle test for wrist extensors, modified ashworth scale and upper limb functional index scoring was done before and after sessions. data was collected from a private clinic of pwd rawalpindi. the statistical values of result showed no significant change in between both the groups, before and after treatment. but a significant improvement was about observed within the group analysis it can be concluded from this study that kinesiotape is an effective treatment method both in inhibiting and facilitating muscular performance. hence both treatments were equally effective. it helps in increasing range of motion and in reducing spasticity.

Eligibility criteria:
inclusion criteria: * age b/w 40 to 90 * limited rom (wrist extension) exclusion criteria: * disoriented * who needs more then moderate support to achieve basic adl and are bed bound * communication gap * allergic to kinesiotaping after being positive to patch test

Keywords: stroke manual muscle testing kinesiotape range of motion upper extremity functional index modified ashworth scale